NeuroOne Medical Technologies financials
$1.09−16.15%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '26 Jun 30 | Q2 '26 Mar 31 | Q1 '26 Dec 31 | Q4 '25 Sep 30 | Q3 '25 Jun 30 | Q2 '25 Mar 31 | Q1 '25 Dec 31 | Q4 '24 Sep 30 | Q3 '24 Jun 30 | Q2 '24 Mar 31 | Q1 '24 Dec 31 | Q4 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $1.9M | $2.9M | $5.7M | $1.7M | $1.4M | $3.3M | $272.3K | $825.8K | $1.4M | $977.6K | $741.8K |
| Gross profit | $1.2M | $990.3K | $1.6M | $4.5M | $914.8K | $771.1K | $1.9M | $141.1K | $281.9K | $390.4K | $266.3K | $193.7K |
| Gross margin | 59.9% | 53.2% | 54.2% | 78.9% | 53.9% | 55.6% | 58.9% | 51.8% | 34.1% | 28.3% | 27.2% | 26.1% |
| Operating income | -$2.4M | -$2.4M | -$1.7M | -$1.4M | -$1.9M | -$2.7M | $1.7M | -$2.8M | -$2.8M | -$2.9M | -$3.4M | -$3.2M |
| Net income | -$2.0M | -$2.4M | -$1.4M | -$1.6M | -$1.5M | -$2.3M | $1.8M | -$3.4M | -$2.8M | -$2.9M | -$3.3M | -$3.1M |
| Net margin | −101.7% | −127.9% | −49.7% | −28.2% | −88.5% | −163.8% | 54.5% | −1230.6% | −335.1% | −207.3% | −342.1% | −422.6% |
| Diluted EPS | $-0.28 | $-0.28 | $-1.08 | $-0.50 | $-0.19 | $-0.44 | $2.16 | $-4.05 | $-3.60 | $-3.96 | $-5.04 | $-5.07 |
| EBITDA | -$2.4M | -$2.3M | -$1.6M | -$1.3M | -$1.8M | -$2.6M | $1.8M | -$2.8M | -$2.7M | -$2.8M | -$3.3M | -$3.1M |
| Operating cash flow | -$1.1M | -$1.3M | -$3.1M | -$1.5M | -$1.5M | -$56.1K | $208.0K | -$2.7M | -$2.4M | -$2.2M | -$3.8M | -$2.9M |
| Free cash flow | -$1.1M | -$1.4M | -$3.2M | -$1.5M | -$1.5M | -$59.3K | $183.6K | -$2.7M | -$2.4M | -$2.2M | -$3.8M | -$3.0M |
| Diluted shares | 8.7M | 8.5M | 1.4M | 3.2M | 8.1M | 5.2M | 0.9M | 0.8M | 0.8M | 0.7M | 0.7M | 0.6M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $2.0M | $2.8M | $3.6M | $6.6M | $8.0M | $1.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $6.2M | $7.6M | $8.6M | $10.8M | $10.8M | $4.5M |
| Total liabilities | $2.4M | $2.5M | $2.2M | $3.7M | $2.6M | $3.3M |
| Shareholders' equity | $3.8M | $5.1M | $6.4M | $7.1M | $8.2M | $1.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology